Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases

Xiang-Yang Yao, Wei Liu, Zhi-Yong Li, Hua-Long Xiong, Ying-Ying Su, Ting-Dong Li, Shi-Yin Zhang, Xue-Jie Zhang, Zhao-Feng Bi, Chen-Xi Deng, Cai-Yu Li, Quan Yuan, Jun Zhang, Tian-Ying Zhang, Zhan-Xiang Wang, View ORCID ProfileSheng-Xiang Ge, View ORCID ProfileNing-Shao Xia
doi: https://doi.org/10.1101/2020.07.18.20156810
Xiang-Yang Yao
1First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Liu
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi-Yong Li
1First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hua-Long Xiong
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying-Ying Su
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ting-Dong Li
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shi-Yin Zhang
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue-Jie Zhang
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhao-Feng Bi
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen-Xi Deng
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cai-Yu Li
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quan Yuan
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Zhang
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tian-Ying Zhang
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nsxia@xmu.edu.cn sxge@xmu.edu.cn tyzhang1003@163.com
Zhan-Xiang Wang
1First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nsxia@xmu.edu.cn sxge@xmu.edu.cn tyzhang1003@163.com
Sheng-Xiang Ge
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sheng-Xiang Ge
  • For correspondence: nsxia@xmu.edu.cn sxge@xmu.edu.cn tyzhang1003@163.com
Ning-Shao Xia
2State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ning-Shao Xia
  • For correspondence: nsxia@xmu.edu.cn sxge@xmu.edu.cn tyzhang1003@163.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Knowledge of the host immune response after natural SARS-CoV-2 infection is essential for informing directions of vaccination and epidemiological control strategies against COVID-19. In this study, thirty-four COVID-19 patients were enrolled with 244 serial blood specimens (38.1% after hospital discharge) collected to explore the chronological evolution of neutralizing (NAb), total (TAb), IgM, IgG and IgA antibody in parallel. IgG titers reached a peak later (approximately 35 days postonset) than those of Nab, Ab, IgM and IgA (20∼25 days postonset). After peaking, IgM levels declined with an estimated average half-life of 10.36 days, which was more rapid than those of IgA (51.25 days) and IgG (177.39 days). Based on these half-life data, we estimate that the median times for IgM, IgA and IgG to become seronegative are 4.59 (IQR 4.12-5.03), 7.78 (IQR 6.71-9.16) and 42.72 (IQR 33.75-47.96) months post disease onset. The relative contribution of IgM to NAb was higher than that of IgG (standardized β regression coefficient: 0.53 vs 0.48), so the rapid decline in NAb may be attributed to the rapid decay of IgM in acute phase. However, the relative contribution of IgG to NAb increased and that of IgM further decreased after 6 weeks postonset. It’s assumed that the decline rate of NAb might slow down to the same level as that of IgG over time. This study suggests that SARS-CoV-2 infection induces robust neutralizing and binding antibody responses in patients and that humoral immunity against SARS-CoV-2 acquired by infection may persist for a relatively long time.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by Xiamen Science and Technology Major Project [Grant number: 3502Z2020YJ01 to SX G and 3502Z2020YJ05 to ZX W].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Medical Ethical Committee of the First Affiliated Hospital of Xiamen University.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
Xiang-Yang Yao, Wei Liu, Zhi-Yong Li, Hua-Long Xiong, Ying-Ying Su, Ting-Dong Li, Shi-Yin Zhang, Xue-Jie Zhang, Zhao-Feng Bi, Chen-Xi Deng, Cai-Yu Li, Quan Yuan, Jun Zhang, Tian-Ying Zhang, Zhan-Xiang Wang, Sheng-Xiang Ge, Ning-Shao Xia
medRxiv 2020.07.18.20156810; doi: https://doi.org/10.1101/2020.07.18.20156810
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
Xiang-Yang Yao, Wei Liu, Zhi-Yong Li, Hua-Long Xiong, Ying-Ying Su, Ting-Dong Li, Shi-Yin Zhang, Xue-Jie Zhang, Zhao-Feng Bi, Chen-Xi Deng, Cai-Yu Li, Quan Yuan, Jun Zhang, Tian-Ying Zhang, Zhan-Xiang Wang, Sheng-Xiang Ge, Ning-Shao Xia
medRxiv 2020.07.18.20156810; doi: https://doi.org/10.1101/2020.07.18.20156810

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4875)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5361)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1823)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)